Pfizer has entered into licensing agreements with two pharmaceutical companies based in India, boosting its position in emerging markets and significantly expanding its portfolio of medicines in its Established Products Business Unit. The company has expanded its pact with Aurobindo Pharma Ltd., acquiring rights to 55 solid oral dose products and 5 sterile injectable products for patients in more than 70 emerging market countries. “This deal illustrates the types of innovative partnerships wh...